Product Description
Mechanisms of Action: DRI Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: Australia | Austria | Belgium | Brazil | Canada | Chile | Colombia | Denmark | Dominican Republic | Estonia | Finland | Germany | Hong Kong | Iceland | Ireland | Israel | Japan | Lithuania | Mexico | Netherlands | New Zealand | Norway | Poland | Portugal | Romania | Singapore | South Africa | Spain | Sweden | Switzerland | United Kingdom | United States
Approved Indications: Binge-Eating Disorder | Attention Deficit Disorder with Hyperactivity
Known Adverse Events: Attention Deficit Disorder with Hyperactivity | Abdominal Pain | Dizziness | Pain Unspecified | Insomnia | Anorexia | Constipation | Diarrhea
Company: None
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
![Map of Global Clinical Trials for Lisdexamfetamine](https://pryzm-maps.s3.us-west-2.amazonaws.com/666666current_maps.png)
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|